These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28646686)

  • 1. EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects.
    Gouw AA; Alsema AM; Tijms BM; Borta A; Scheltens P; Stam CJ; van der Flier WM
    Neurobiol Aging; 2017 Sep; 57():133-142. PubMed ID: 28646686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal resting-state EEG in amyloid-positive patients along the Alzheimer's disease continuum: considerations for clinical trials.
    Scheijbeler EP; de Haan W; Stam CJ; Twisk JWR; Gouw AA
    Alzheimers Res Ther; 2023 Oct; 15(1):182. PubMed ID: 37858173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease.
    Gaubert S; Raimondo F; Houot M; Corsi MC; Naccache L; Diego Sitt J; Hermann B; Oudiette D; Gagliardi G; Habert MO; Dubois B; De Vico Fallani F; Bakardjian H; Epelbaum S;
    Brain; 2019 Jul; 142(7):2096-2112. PubMed ID: 31211359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing.
    Rowe CC; Bourgeat P; Ellis KA; Brown B; Lim YY; Mulligan R; Jones G; Maruff P; Woodward M; Price R; Robins P; Tochon-Danguy H; O'Keefe G; Pike KE; Yates P; Szoeke C; Salvado O; Macaulay SL; O'Meara T; Head R; Cobiac L; Savage G; Martins R; Masters CL; Ames D; Villemagne VL
    Ann Neurol; 2013 Dec; 74(6):905-13. PubMed ID: 24448836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative EEG as a biomarker in mild cognitive impairment with Lewy bodies.
    Schumacher J; Taylor JP; Hamilton CA; Firbank M; Cromarty RA; Donaghy PC; Roberts G; Allan L; Lloyd J; Durcan R; Barnett N; O'Brien JT; Thomas AJ
    Alzheimers Res Ther; 2020 Jul; 12(1):82. PubMed ID: 32641111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative Frequency Power of EEG Correlates with Progression of Mild Cognitive Impairment to Dementia in Parkinson's Disease.
    Gu Y; Chen J; Lu Y; Pan S
    Clin EEG Neurosci; 2016 Apr; 47(2):113-7. PubMed ID: 25519446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment.
    Pyun JM; Park YH; Kim HR; Suh J; Kang MJ; Kim BJ; Youn YC; Jang JW; Kim S;
    Alzheimers Res Ther; 2017 Dec; 9(1):99. PubMed ID: 29246250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease.
    Tijms BM; Ten Kate M; Gouw AA; Borta A; Verfaillie S; Teunissen CE; Scheltens P; Barkhof F; van der Flier WM
    Neurobiol Aging; 2018 Jan; 61():75-81. PubMed ID: 29040871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints.
    van Harten AC; Visser PJ; Pijnenburg YA; Teunissen CE; Blankenstein MA; Scheltens P; van der Flier WM
    Alzheimers Dement; 2013 Sep; 9(5):481-7. PubMed ID: 23232269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment.
    Ten Kate M; Barkhof F; Visser PJ; Teunissen CE; Scheltens P; van der Flier WM; Tijms BM
    Alzheimers Res Ther; 2017 Sep; 9(1):73. PubMed ID: 28899429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.
    Vos SJ; Verhey F; Frölich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Morbelli S; Frisoni GB; Drzezga A; Didic M; van Berckel BN; Simmons A; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Lovestone S; Muscio C; Herukka SK; Salmon E; Bastin C; Wallin A; Nordlund A; de Mendonça A; Silva D; Santana I; Lemos R; Engelborghs S; Van der Mussele S; ; Freund-Levi Y; Wallin ÅK; Hampel H; van der Flier W; Scheltens P; Visser PJ
    Brain; 2015 May; 138(Pt 5):1327-38. PubMed ID: 25693589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative EEG of Rapid-Eye-Movement Sleep: A Marker of Amnestic Mild Cognitive Impairment.
    Brayet P; Petit D; Frauscher B; Gagnon JF; Gosselin N; Gagnon K; Rouleau I; Montplaisir J
    Clin EEG Neurosci; 2016 Apr; 47(2):134-41. PubMed ID: 26323578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative EEG in progressing vs stable mild cognitive impairment (MCI): results of a 1-year follow-up study.
    Luckhaus C; Grass-Kapanke B; Blaeser I; Ihl R; Supprian T; Winterer G; Zielasek J; Brinkmeyer J
    Int J Geriatr Psychiatry; 2008 Nov; 23(11):1148-55. PubMed ID: 18537220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly.
    Slot RE; Van Harten AC; Kester MI; Jongbloed W; Bouwman FH; Teunissen CE; Scheltens P; Veerhuis R; van der Flier WM
    J Alzheimers Dis; 2017; 56(2):687-697. PubMed ID: 28035918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.